Radioiodine-resistant differentiated thyroid cancer: Hope for the future

ONCOLOGY

Volumn 23, Issue 9, 2009, Pages

  Hodak, Steven P ^a   Carty, Sally E ^b  

^a Department of Medicine ^*

^b UNIVERSITY OF PITTSBURGH SCHOOL OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

B RAF KINASE; FLUORODEOXYGLUCOSE F 18; K RAS PROTEIN; RADIOACTIVE IODINE; SORAFENIB; SUNITINIB;

CANCER CHEMOTHERAPY; CANCER MORTALITY; CANCER RESISTANCE; DRUG UPTAKE; GENE MUTATION; HUMAN; MEDICAL DECISION MAKING; METASTASIS; NOTE; PATIENT SELECTION; POSITRON EMISSION TOMOGRAPHY; THYROID CANCER;

EID: 70349292896     PISSN: 08909091     EISSN: 08909091     Source Type: Journal    
DOI: None     Document Type: Note

References (5)

1. Robbins RJ: Real-time prognosis for metastatic thyroid carcinoma based on 2-[18F]fluoro-2-deoxy-D-glucose-positron emission tomography scanning. J Clin Endocrinol Metab 91:498-505, 2006.
2. Xing M, Clark D, Guan H, et al: BRAF mutation testing of thyroid fine-needle aspiration biopsy specimens for preoperative risk stratification in papillary thyroid cancer. J Clin Oncol 27:2977-2982, 2009.
3. Yip L, Nikiforova MN, Carty SE, et al: Optimizing surgical treatment of papillary thyroid carcinoma associated with BRAF mutation. Surgery. In press.
4. Nikiforov YE: Thyroid carcinoma: Molecular pathways and therapeutic targets. Modern Pathology 21(suppl 2):S37-S43, 2008. (Pubitemid 351592770)
5. Sherman SI: Advances in chemotherapy of differentiated epithelial and medullary thyroid cancers. J Clin Endocrinol Metab 94:1493-1499, 2009.